Skip to content
Accelerating Early-Stage Biotechs episode artwork

Apr 18, 2019 29 min

Accelerating Early-Stage Biotechs

from The Bio Report Hosted by Levine Media Group

The effort to cost-effectively accelerate the development of new therapies has led to the rise of new business models that seek to provide expertise, capital, and access to professional networks that can help early-stage companies navigate pitfalls and overcome challenges. Xontogeny is a bit of a hybrid in its approach, preferring the term aggregator to accelerator or incubator. We spoke to Chris Garabedian, chairman and CEO of Xontogeny, about the company’s approach, what it looks for in the biotechs it backs, and what he’s learned from his own experience as a biotech executive that he thinks will benefit others.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Accelerating Early-Stage Biotechs

0:00 29:03

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of The Bio Report?

This episode is 29 minutes long.

When was this The Bio Report episode published?

This episode was published on April 18, 2019.

Can I download this The Bio Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.